FDA Approves Penpulimab for Non-Keratinizing Nasopharyngeal Carcinoma

The FDA has approved penpulimab-kcqx (Akeso Biopharma) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). The agency also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.

The efficacy of penpulimab-kcqx with cisplatin or carboplatin